Cocrystal Pharma shares surge 43.14% intraday as FDA grants fast track designation for CDI-988, a first-in-class oral antiviral candidate for norovirus.

Cocrystal Pharma surged 43.14% intraday, driven by the company announcing that the FDA granted Fast Track designation to its oral direct-acting protease inhibitor CDI-988 on April 2, 2026, for the treatment and prevention of norovirus infection. On March 31, 2026, the company disclosed that the Phase 1b norovirus challenge trial for CDI-988 had begun at Emory University School of Medicine, evaluating the drug's preventive and therapeutic effects in healthy subjects.